Improved cardiac function by Ganoderma lucidum spore oil in high-altitude residents: A single-arm trials

Background: Ganoderma lucidum spore oil (GLSO) contains small molecules that are efficiently absorbed into the bloodstream upon oral administration. Previous studies suggest potential cardio-protective roles of GLSO, relevant for myocardial injury (MI) patients. Purpose: To evaluate the effects of GLSO on cardiac function in MI patients residing at high altitudes (above 3500 m), we focused on the improvements of ventricular function, alterations in energy metabolism, and modulation of gut microbiota. Study design: A single-arm clinical trial was performed involving 38 Tibetan MI patients to assess the efficacy of GLSO over eight-week treatment. Methods: Patients received GLSO orally for eight weeks, followed by cardiac assessment, metabolomic analysis, and gut microbiota analysis. Results: Cardiac functional improvements were observed with enhanced left ventricular diastolic performance and reduced cardiac regurgitation in 47.06 % of patients. A decrease in electrocardiographic abnormalities was detected in 77.78 % of patients. Metabolomic profiling revealed significant reductions in fatty acids and acylcarnitines, with concurrent increases in bile acids and β-alanine levels. Gut microbiota analysis indicated increased microbial diversity and a notable rise in Akkermansia populations. Conclusion: The GLSO oral preparation appears to improve cardiac function in high-altitude MI patients. These benefits may be mediated through enhanced β-oxidation of fatty acids and favorable modulation of gut microbiota. Our study suggests a promising therapeutic role for GLSO in this patient population.